![Transparency Market Researchが調査・発行した産業分析レポートです。放射性医薬品セラノスティクスの世界市場2021年ｰ2031年：放射性同位元素別（テクネチウム-99、ガリウム-68、ヨウ素-131、ヨウ素-123、18F、Y-90、ルテチウム（Lu）177、銅（Cu）67、銅（Cu）64、その他）、用途別、ソース別、エンドユーザー別、アプローチ別 / Radiopharmaceutical Theranostics Market (Radioisotope: Technetium-99, Gallium-68, Iodine-131, Iodine-123, 18F, Y-90, Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, and Others; Application: Oncology, Cardiology, and Others; Source: Nuclear Reactors and Cyclotrons; End User: Hospitals, Academic & Research Institutes, and Others; and Approach: Targeted Therapeutic [Rx] and Companion Diagnostic [DX]) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031 / MRC2111A060資料のイメージです。](https://www.marketresearch.co.jp/images-folder2/report-contents-26.gif) | • レポートコード：MRC2111A060 • 出版社/出版日：Transparency Market Research / 2021年7月29日 • レポート形態：英文、PDF、257ページ • 納品方法：Eメール • 産業分類：医薬品 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Site Licence | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Enterprisewide | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Transparency Market Research社の本調査資料では、放射性医薬品セラノスティクスの世界市場を広く調査・分析し、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、キーインサイト、放射性同位元素別（テクネチウム-99、ガリウム-68、ヨウ素-131、ヨウ素-123、18F）分析、用途別分析、ソース別分析、アプローチ別分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などの項目を掲載しています。 ・序論 ・仮定・調査手法 ・エグゼクティブサマリー ・市場概要 ・キーインサイト ・放射性医薬品セラノスティクスの世界市場規模：放射性同位元素別（テクネチウム-99、ガリウム-68、ヨウ素-131、ヨウ素-123、18F） ・放射性医薬品セラノスティクスの世界市場規模：用途別 ・放射性医薬品セラノスティクスの世界市場規模：ソース別 ・放射性医薬品セラノスティクスの世界市場規模：アプローチ別 ・放射性医薬品セラノスティクスの世界市場規模：地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ） ・競争状況 |
Radiopharmaceutical Theranostics Market – Scope of Report
TMR’s report on the global radiopharmaceutical theranostics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2021 to 2031. The report provides revenue of the global radiopharmaceutical theranostics market for the period of 2017–2031, considering 2020 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global radiopharmaceutical theranostics market from 2021 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the radiopharmaceutical theranostics market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global radiopharmaceutical theranostics market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global radiopharmaceutical theranostics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global radiopharmaceutical theranostics market.
The report delves into the competitive landscape of the global radiopharmaceutical theranostics market. Key players operating in the global radiopharmaceutical theranostics market have been identified and each one of these is profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global radiopharmaceutical theranostics market profiled in this report.
Key Questions Answered in Radiopharmaceutical Theranostics Market Report
What is the sales/revenue generated by the radiopharmaceutical theranostics market across all regions during the forecast period?
What are the opportunities in the global radiopharmaceutical theranostics market?
What are the major drivers, restraints, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which segment is expected to generate the highest revenue globally in 2031?
Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?
Radiopharmaceutical Theranostics Market – Research Objectives and Research Approach
The comprehensive report on the global radiopharmaceutical theranostics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global radiopharmaceutical theranostics market in terms of radioisotope, application, source, end user, approach, and region. Key segments under each criterion are studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global radiopharmaceutical theranostics market.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Radiopharmaceutical Theranostics Market
4. Market Overview
4.1. Introduction
4.1.1. Radioisotope Market Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Overview of Radiopharmaceuticals market
5.2. FDA Approved Radiopharmaceuticals Products
5.3. Overview of Radiopharamceutical Diagnostic Market
5.4. Overview of Radiopharamceutical Therapy Market
5.5. Regulatory Scenario
5.6. Current and Future Radiopharmaceutical Theranostics Pairs
5.7. COVID-19 Impact Analysis
6. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by Radioisotope
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Radioisotope, 2017–2031
6.3.1. Technetium-99
6.3.2. Gallium-68
6.3.3. Iodine-131
6.3.4. Iodine-123
6.3.5. 18F
6.3.6. Y-90
6.3.7. Lutetium (Lu) 177
6.3.8. Copper (Cu) 67
6.3.9. Copper (Cu) 64
6.3.10. Others
6.4. Market Attractiveness Analysis, by Radioisotope
7. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by Application
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Application, 2017–2031
7.3.1. Oncology
7.3.2. Cardiology
7.3.3. Others
7.4. Market Attractiveness Analysis, by Application
8. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by Source
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Source, 2017–2031
8.3.1. Nuclear Reactors
8.3.2. Cyclotrons
8.4. Market Attractiveness Analysis, by Source
9. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by Approach
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by Approach, 2017–2031
9.3.1. Targeted Therapeutic (Rx)
9.3.2. Companion Diagnostic (DX)
9.4. Market Attractiveness Analysis, by Approach
10. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by End-user
10.1. Introduction & Definition
10.2. Key Findings / Developments
10.3. Market Value Forecast, by End-user, 2017–2031
10.3.1. Hospitals
10.3.2. Academic & Research Institutes
10.3.3. Others
10.4. Market Attractiveness Analysis, by End-user
11. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by Region
11.1. Key Findings
11.2. Market Value Forecast, by Region
11.2.1. North America
11.2.2. Europe
11.2.3. Asia Pacific
11.2.4. Latin America
11.2.5. Middle East & Africa
11.3. Market Attractiveness Analysis, by Country/Region
12. North America Radiopharmaceutical Theranostics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Radioisotope, 2017–2031
12.2.1. Technetium-99
12.2.2. Gallium-68
12.2.3. Iodine-131
12.2.4. Iodine-123
12.2.5. 18F
12.2.6. Y-90
12.2.7. Lutetium (Lu) 177
12.2.8. Copper (Cu) 67
12.2.9. Copper (Cu) 64
12.2.10. Others
12.3. Market Value Forecast, by Application, 2017–2031
12.3.1. Oncology
12.3.2. Cardiology
12.3.3. Others
12.4. Market Value Forecast, by Source, 2017–2031
12.4.1. Nuclear Reactors
12.4.2. Cyclotrons
12.5. Market Value Forecast, by Approach, 2017–2031
12.5.1. Targeted Therapeutic (Rx)
12.5.2. Companion Diagnostic (DX)
12.6. Market Value Forecast, by End-user, 2017–2031
12.6.1. Hospitals
12.6.2. Academic & Research Institutes
12.6.3. Others
12.7. Market Value Forecast, by Country, 2017–2031
12.7.1. U.S.
12.7.2. Canada
12.8. Market Attractiveness Analysis
12.8.1. By Radioisotope
12.8.2. By Application
12.8.3. By Source
12.8.4. By Approach
12.8.5. By End-user
12.8.6. By Country
13. Europe Radiopharmaceutical Theranostics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Radioisotope, 2017–2031
13.2.1. Technetium-99
13.2.2. Gallium-68
13.2.3. Iodine-131
13.2.4. Iodine-123
13.2.5. 18F
13.2.6. Y-90
13.2.7. Lutetium (Lu) 177
13.2.8. Copper (Cu) 67
13.2.9. Copper (Cu) 64
13.2.10. Others
13.3. Market Value Forecast, by Application, 2017–2031
13.3.1. Oncology
13.3.2. Cardiology
13.3.3. Others
13.4. Market Value Forecast, by Source, 2017–2031
13.4.1. Nuclear Reactors
13.4.2. Cyclotrons
13.5. Market Value Forecast, by Approach, 2017–2031
13.5.1. Targeted Therapeutic (Rx)
13.5.2. Companion Diagnostic (DX)
13.6. Market Value Forecast, by End-user, 2017–2031
13.6.1. Hospitals
13.6.2. Academic & Research Institutes
13.6.3. Others
13.7. Market Value Forecast, by Country/Sub-region, 2017–2031
13.7.1. Germany
13.7.2. U.K.
13.7.3. France
13.7.4. Italy
13.7.5. Spain
13.7.6. Rest of Europe
13.8. Market Attractiveness Analysis
13.8.1. By Radioisotope
13.8.2. By Application
13.8.3. By Source
13.8.4. By Approach
13.8.5. By End-user
13.8.6. By Country/Sub-region
14. Asia Pacific Radiopharmaceutical Theranostics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Radioisotope, 2017–2031
14.2.1. Technetium-99
14.2.2. Gallium-68
14.2.3. Iodine-131
14.2.4. Iodine-123
14.2.5. 18F
14.2.6. Y-90
14.2.7. Lutetium (Lu) 177
14.2.8. Copper (Cu) 67
14.2.9. Copper (Cu) 64
14.2.10. Others
14.3. Market Value Forecast, by Application, 2017–2031
14.3.1. Oncology
14.3.2. Cardiology
14.3.3. Others
14.4. Market Value Forecast, by Source, 2017–2031
14.4.1. Nuclear Reactors
14.4.2. Cyclotrons
14.5. Market Value Forecast, by Approach, 2017–2031
14.5.1. Targeted Therapeutic (Rx)
14.5.2. Companion Diagnostic (DX)
14.6. Market Value Forecast, by End-user, 2017–2031
14.6.1. Hospitals
14.6.2. Academic & Research Institutes
14.6.3. Others
14.7. Market Value Forecast, by Country/Sub-region, 2017–2031
14.7.1. Japan
14.7.2. China
14.7.3. India
14.7.4. Australia & New Zealand
14.7.5. Rest of Asia Pacific
14.8. Market Attractiveness Analysis
14.8.1. By Radioisotope
14.8.2. By Application
14.8.3. By Source
14.8.4. By Approach
14.8.5. By End-user
14.8.6. By Country/Sub-region
15. Latin America Radiopharmaceutical Theranostics Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast By Radioisotope, 2017–2031
15.2.1. Technetium-99
15.2.2. Gallium-68
15.2.3. Iodine-131
15.2.4. Iodine-123
15.2.5. 18F
15.2.6. Y-90
15.2.7. Lutetium (Lu) 177
15.2.8. Copper (Cu) 67
15.2.9. Copper (Cu) 64
15.2.10. Others
15.3. Market Value Forecast, by Application, 2017–2031
15.3.1. Oncology
15.3.2. Cardiology
15.3.3. Others
15.4. Market Value Forecast, by Source, 2017–2031
15.4.1. Nuclear Reactors
15.4.2. Cyclotrons
15.5. Market Value Forecast, by Approach, 2017–2031
15.5.1. Targeted Therapeutic (Rx)
15.5.2. Companion Diagnostic (DX)
15.6. Market Value Forecast, by End-user, 2017–2031
15.6.1. Hospitals
15.6.2. Academic & Research Institutes
15.6.3. Others
15.7. Market Value Forecast, by Country/Sub-region, 2017–2031
15.7.1. Brazil
15.7.2. Mexico
15.7.3. Rest of Latin America
15.8. Market Attractiveness Analysis
15.8.1. By Radioisotope
15.8.2. By Application
15.8.3. By Source
15.8.4. By Approach
15.8.5. By End-user
15.8.6. By Country/Sub-region
16. Middle East & Africa Radiopharmaceutical Theranostics Market Analysis and Forecast
16.1. Introduction
16.1.1. Key Findings
16.2. Market Value Forecast, by Radioisotope, 2017–2031
16.2.1. Technetium-99
16.2.2. Gallium-68
16.2.3. Iodine-131
16.2.4. Iodine-123
16.2.5. 18F
16.2.6. Y-90
16.2.7. Lutetium (Lu) 177
16.2.8. Copper (Cu) 67
16.2.9. Copper (Cu) 64
16.2.10. Others
16.3. Market Value Forecast, by Application, 2017–2031
16.3.1. Oncology
16.3.2. Cardiology
16.3.3. Others
16.4. Market Value Forecast, by Source, 2017–2031
16.4.1. Nuclear Reactors
16.4.2. Cyclotrons
16.5. Market Value Forecast, by Approach, 2017–2031
16.5.1. Targeted Therapeutic (Rx)
16.5.2. Companion Diagnostic (DX)
16.6. Market Value Forecast, by End-user, 2017–2031
16.6.1. Hospitals
16.6.2. Academic & Research Institutes
16.6.3. Others
16.7. Market Value Forecast, by Country/Sub-region, 2017–2031
16.7.1. GCC Countries
16.7.2. South Africa
16.7.3. Rest of Middle East & Africa
16.8. Market Attractiveness Analysis
16.8.1. By Radioisotope
16.8.2. By Application
16.8.3. By Source
16.8.4. By Approach
16.8.5. By End-user
16.8.6. By Country/Sub-region
17. Competition Landscape
17.1. Market Player – Competition Matrix (by tier and size of companies)
17.2. Company Profiles
17.2.1. Nihon Medi-Physics
17.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
17.2.1.2. Company Financials
17.2.1.3. Growth Strategies
17.2.1.4. SWOT Analysis
17.2.2. ITM Isotopen Technologien München AG
17.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
17.2.2.2. Company Financials
17.2.2.3. Growth Strategies
17.2.2.4. SWOT Analysis
17.2.3. Advanced Accelerator Applications
17.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
17.2.3.2. Company Financials
17.2.3.3. Growth Strategies
17.2.3.4. SWOT Analysis
17.2.4. Telix Pharmaceuticals
17.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
17.2.4.2. Company Financials
17.2.4.3. Growth Strategies
17.2.4.4. SWOT Analysis
17.2.5. GE Healthcare
17.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
17.2.5.2. Company Financials
17.2.5.3. Growth Strategies
17.2.5.4. SWOT Analysis
17.2.6. Theragnostics Ltd
17.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
17.2.6.2. Company Financials
17.2.6.3. Growth Strategies
17.2.6.4. SWOT Analysis
17.2.7. NuView Life Sciences
17.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
17.2.7.2. Company Financials
17.2.7.3. Growth Strategies
17.2.7.4. SWOT Analysis
17.2.8. Jubilant Pharma Limited
17.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
17.2.8.2. Company Financials
17.2.8.3. Growth Strategies
17.2.8.4. SWOT Analysis
17.2.9. Lantheus Holdings, Inc.
17.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
17.2.9.2. Company Financials
17.2.9.3. Growth Strategies
17.2.9.4. SWOT Analysis
17.2.10. Curium Pharma
17.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)
17.2.10.2. Company Financials
17.2.10.3. Growth Strategies
17.2.10.4. SWOT Analysis
17.2.11. Bayer AG
17.2.11.1. Company Overview (HQ, Business Segments, Employee Strength)
17.2.11.2. Company Financials
17.2.11.3. Growth Strategies
17.2.11.4. SWOT Analysis
17.2.12. Clarity Pharmaceuticals
17.2.12.1. Company Overview (HQ, Business Segments, Employee Strength)
17.2.12.2. Company Financials
17.2.12.3. Growth Strategies
17.2.12.4. SWOT Analysis
Table 01: FDA Approved Radiopharmaceuticals Products
Table 02: FDA Approved Radiopharmaceuticals Products
Table 03: FDA Approved Radiopharmaceuticals Products
Table 04: Radiopharmaceuticals used in diagnostic applications along with their important physical properties
Table 05: Radiopharmaceuticals used in therapeutic applications along with their important physical properties
Table 06: List of Current and Future Radiopharmaceutical Theranostics Pairs
Table 07: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn) Forecast, by Radioisotope, 2017–2031
Table 08: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn) Forecast, by Application, 2017–2031
Table 09: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn) Forecast, by Source, 2017–2031
Table 10: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn) Forecast, by Approach, 2017–2031
Table 11: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn) Forecast, by End-user, 2017–2031
Table 12: Global Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 13: North America Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 14: North America Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radioisotope, 2017–2031
Table 15: North America Radiopharmaceutical Theranostics Market Revenue (US$ Mn) Forecast, by Application, 2017–2031
Table 16: North America Radiopharmaceutical Theranostics Market Revenue (US$ Mn) Forecast, by Source, 2017–2031
Table 17: North America Radiopharmaceutical Theranostics Market Revenue (US$ Mn) Forecast, by Approach, 2017–2031
Table 18: North America Radiopharmaceutical Theranostics Market Revenue (US$ Mn) Forecast, by End-user, 2017–2031
Table 19: Europe Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 20: Europe Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radioisotope, 2017–2031
Table 21: Europe Radiopharmaceutical Theranostics Market Revenue (US$ Mn) Forecast, by Application, 2017–2031
Table 22: Europe Radiopharmaceutical Theranostics Market Revenue (US$ Mn) Forecast, by Source, 2017–2031
Table 23: Europe Radiopharmaceutical Theranostics Market Revenue (US$ Mn) Forecast, by Approach, 2017–2031
Table 24: Europe Radiopharmaceutical Theranostics Market Revenue (US$ Mn) Forecast, by End-user, 2017–2031
Table 25: Asia Pacific Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 26: Asia Pacific Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radioisotope, 2017–2031
Table 27: Asia Pacific Radiopharmaceutical Theranostics Market Revenue (US$ Mn) Forecast, by Application, 2017–2031
Table 28: Asia Pacific Radiopharmaceutical Theranostics Market Revenue (US$ Mn) Forecast, by Source, 2017–2031
Table 29: Asia Pacific Radiopharmaceutical Theranostics Market Revenue (US$ Mn) Forecast, by Approach, 2017–2031
Table 30: Asia Pacific Radiopharmaceutical Theranostics Market Revenue (US$ Mn) Forecast, by End-user, 2017–2031
Table 31: Latin America Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 32: Latin America Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radioisotope, 2017–2031
Table 33: Latin America Radiopharmaceutical Theranostics Market Revenue (US$ Mn) Forecast, by Application, 2017–2031
Table 34: Latin America Radiopharmaceutical Theranostics Market Revenue (US$ Mn) Forecast, by Source, 2017–2031
Table 35: Latin America Radiopharmaceutical Theranostics Market Revenue (US$ Mn) Forecast, by Approach, 2017–2031
Table 36: Latin America Radiopharmaceutical Theranostics Market Revenue (US$ Mn) Forecast, by End-user, 2017–2031
Table 37: Middle East & Africa Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 38: Middle East & Africa Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radioisotope, 2017–2031
Table 39: Middle East & Africa Radiopharmaceutical Theranostics Market Revenue (US$ Mn) Forecast, by Application, 2017–2031
Table 40: Middle East & Africa Radiopharmaceutical Theranostics Market Revenue (US$ Mn) Forecast, by Source, 2017–2031
Table 41: Middle East & Africa Radiopharmaceutical Theranostics Market Revenue (US$ Mn) Forecast, by Approach, 2017–2031
Table 42: Middle East & Africa Radiopharmaceutical Theranostics Market Revenue (US$ Mn) Forecast, by End-user, 2017–2031